DR. JOHN LOUIS RUBENSTEIN, M.D.
Neurology in San Francisco, CA
License number
California G61069
Category
Neurology
Type
Neurology
Address
Address
1550 Rock Hall ROOM 284C, San Francisco, CA 94158
Phone
(415) 476-7862
Personal information
See more information about JOHN LOUIS RUBENSTEIN at radaris.comName
Address
Phone
1220 Colusa Ave, Berkeley, CA 94707
2175 Euclid Ave, El Cajon, CA 92019
71 Woodland Ave #73, San Francisco, CA 94117
71 Woodland Ave, San Francisco, CA 94117
1220 Colusa Ave, Berkeley, CA 94707
Professional information
Professor At Ucsf
Position:
professor at ucsf, Professor at University of California, San Francisco
Location:
San Francisco Bay Area
Industry:
Biotechnology
Work:
ucsf
-
professor
University of California, San Francisco
since 1991
-
Professor
Dr. John L Rubenstein, San Francisco CA - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Psychiatry)
Address:
1550 4Th St SUITE 284C, San Francisco 94158
(415) 476-7862 (Phone)
(415) 476-7862 (Phone)
Certifications:
Psychiatry, 1993
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Stanford University
Graduated: 1986
Stanford University Hospital
Stanford University
Graduated: 1986
Stanford University Hospital
Production Of Gabaergic Cells
US Patent:
6602680, Aug 5, 2003
Filed:
Jul 5, 2001
Appl. No.:
09/900527
Inventors:
John L. Rubenstein - San Francisco CA
Marina Mione - London, GB
Stewart Anderson - San Francisco CA
Thorsten Stuehmer - San Francisco CA
Kyuson Yun - San Francisco CA
Marina Mione - London, GB
Stewart Anderson - San Francisco CA
Thorsten Stuehmer - San Francisco CA
Kyuson Yun - San Francisco CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12Q 168
US Classification:
435 29, 435 6, 4353201, 435455, 536 231, 536 232, 536 235, 424 937
Abstract:
The invention features methods and compositions for the production of GABAergic cells, particularly GABAergic neurons. Production of GABAergic cells is accomplished by increasing activity of a Dlx gene (e. g. , DLX1, DLX2, or DLX5) in an immature neuronal cell. The increase in Dlx activity causes differentiation of the immature neuronal cell into a neuronal cell exhibiting the GABAergic phenotype. The invention also encompasses use of GABAergic cells produced by the method of the invention in, for example, identification of agents that affect GABAergic cell activity and survival, and in replacement therapy.
Genetic Demonstration Of Requirement For Nkx6.1, Nkx2.2 And Nkx6.2 In Ventral Neuron Generation
US Patent:
2004005, Mar 18, 2004
Filed:
Aug 1, 2003
Appl. No.:
10/362437
Inventors:
Thomas Jessell - Bronx NY, US
James Briscoe - London W69EN, GB
Johan Ericson - Hasselby, SE
John Rubenstein - San Francisco CA, US
Maike Sander - Hamburg, DE
James Briscoe - London W69EN, GB
Johan Ericson - Hasselby, SE
John Rubenstein - San Francisco CA, US
Maike Sander - Hamburg, DE
International Classification:
C12Q001/00, C12N015/87
US Classification:
435/004000, 435/466000, 435/264000
Abstract:
This invention provides a method of converting a stem cell into a ventral neuron which comprises introducing into the stem cell a nucleic acid which expresses homeodomain transcription factor Nkx6.1 or Nkx6.2 protein in the stem cell so as to thereby convert the stem cell into the ventral neuron. Provided are methods of diagnosing a motor neuron degenerative disease in a subject. Also provides is a method of treating neuronal degeneration in a subjet which comprises implanting in diseased neural tissue of the subject a neural stem cell which is capable of expressing homeodomain Nkx6.1 or Nkx6.2 protein under conditions such that the stem cell is converted into a motor neuron after implantation, thereby treating neuronal degeneration in the subject.
Nkx-2.2 And Nkx-6.1 Transgenic Mouse Models For Diabetes, Depression, And Obesity
US Patent:
6127598, Oct 3, 2000
Filed:
Jul 25, 1997
Appl. No.:
8/900510
Inventors:
Michael S. German - San Francisco CA
John L.R. Rubenstein - San Francisco CA
Lori Sussel - San Francisco CA
Maike Sander - San Francisco CA
Roger A. Pedersen - San Francisco CA
Juanito J. Meneses - San Francisco CA
John L.R. Rubenstein - San Francisco CA
Lori Sussel - San Francisco CA
Maike Sander - San Francisco CA
Roger A. Pedersen - San Francisco CA
Juanito J. Meneses - San Francisco CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12N 1509, C12N 1563, C12N 1500, C12N 500
US Classification:
800 18
Abstract:
The present invention features mouse models for Nkx-2. 2 gene function and for Nkx-6. 1 gene function, wherein the transgenic mouse is characterized by having a defect in Nkx-2. 2 gene function or a defect in Nkx-6. 1 gene function (where, because Nkx-2. 2 acts upstream of Nkx-6. 1, a defect in Nkx-2. 2 gene function affects Nkx-6. 1 gene function) and by having a decreased number of insulin-producing cells relative to a normal mouse. Where the transgenic mouse contains a defect in Nkx-2. 2 gene function, the mouse is further characterized by a decreased number of serotonin-producing cells relative to a normal mouse. The transgenic mice may be either homozygous or heterozygous for the Nkx-2. 2 or Nkx-6. 1 defect.
Transplantation Of Neural Cells
US Patent:
2009031, Dec 17, 2009
Filed:
Jan 18, 2007
Appl. No.:
12/161527
Inventors:
Scott C. Baraban - Novato CA, US
John L. Rubenstein - San Francisco CA, US
Arturo Alvarez-Buylla - Woodside CA, US
John L. Rubenstein - San Francisco CA, US
Arturo Alvarez-Buylla - Woodside CA, US
International Classification:
A61K 35/00, A61P 25/00
US Classification:
424 937
Abstract:
Restoration or increase of inhibitory interneuron function in vivo is achieved by transplantation of MGE cells into the brain. Compositions containing MGE cells are provided as are uses to treat various diseases characterised by abnormal inhibitory interneuron function or in cases where increase inhibition may ameliorate neural circuits that are abnormally activated.
Ameliorating Nervous Systems Disorders
US Patent:
2011016, Jul 7, 2011
Filed:
May 5, 2009
Appl. No.:
12/991367
Inventors:
Arnold Kriegstein - Mill Valley CA, US
John L.R. Rubenstein - San Francisco CA, US
Scott C. Baraban - Novato CA, US
Arturo Alvarez-Buylla - Woodside CA, US
John L.R. Rubenstein - San Francisco CA, US
Scott C. Baraban - Novato CA, US
Arturo Alvarez-Buylla - Woodside CA, US
International Classification:
A61K 35/12, A61P 25/00
US Classification:
424 937
Abstract:
The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.